{"success":true,"data":{"pressRelease":{"id":"138849","rtpr_id":"nGNX4rvdg1-20260909","ticker":"MSLE","exchange":"NASDAQ","all_tickers":["MSLE","MSCL"],"title":"Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247","author":"Globe Newswire","published_at":"2026-09-09T11:00:01.356Z","article_body":"TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience (Nasdaq: MSLE,\nTSX: MSCL), a clinical-stage drug development company developing\nlife-improving medicines to treat degenerative muscle diseases, today\nannounced the assignment of the International Nonproprietary Name (INN)\n“forazapadin” for the Company's orally administered, small molecule drug\ncandidate designed to restore muscle regeneration that was previously known as\nSAT-3247.\n\n“As we continue to execute our clinical development strategies, this naming\ndesignation reflects the maturity of the program and supports its future\ndevelopment as we plan for regulatory submission and commercialization in\nDuchenne muscular dystrophy,” said Frank Gleeson, co-founder and chief\nexecutive officer of Satellos. “Importantly, it comes amid a period of\nsignificant momentum across our Duchenne clinical programs, notably the\nexpected completion of enrollment this quarter in the BASECAMP study and the\nrelease of clinical data from the BASECAMP study, which is expected in the\nfourth quarter.”\n\nThe INN, assigned through the World Health Organization naming process,\nestablishes a globally recognized, nonproprietary name for the therapy as\nforazapadin advances through clinical development and toward potential\ncommercialization. Forazapadin is currently being evaluated in two Phase 2\nstudies in patients with Duchenne muscular dystrophy (DMD) and the company\nintends to begin a Phase 2 clinical trial in facioscapulohumeral muscular\ndystrophy (FSHD) by the end of 2026.\n\nABOUT FORAZAPADIN\n\nForazapadin is a proprietary, oral, small molecule drug candidate being\ndeveloped by Satellos as a novel approach to regenerating skeletal muscle lost\nin DMD and other degenerative muscle diseases or injury conditions.\nForazapadin targets AAK1, a key protein identified by Satellos as capable of\nhelping restore the body’s natural muscle repair and regeneration biology, a\nfundamental process that is disrupted in DMD and other degenerative\nconditions. By inhibiting AAK1, forazapadin treatment aims to re-establish a\nbiochemical signal needed to support muscle regeneration. Satellos is\nadvancing forazapadin as a potential treatment for DMD that is independent of\ndystrophin and applicable regardless of exon mutation status as either a\nstand-alone or adjunctive therapy, with ongoing Phase 2 clinical studies\nincluding BASECAMP, a global, randomized, placebo-controlled study in\npediatric participants, and TRAILHEAD, an open-label study in adult\nparticipants.\n\nThe Company previously referred to the program as SAT-3247 and expects to\ntransition to broader use of the INN in future scientific, regulatory and\ncorporate communications.\n\nABOUT SATELLOS BIOSCIENCE INC.\n\nSatellos is a clinical-stage drug development company focused on restoring\nnatural muscle repair and regeneration in degenerative muscle diseases.\nThrough its research, Satellos has developed forazapadin, an orally\nadministered small molecule AAK1 inhibitor designed to address deficits in\nmuscle repair and regeneration. Forazapadin is being evaluated as a potential\ndisease-modifying treatment, for DMD in two Phase 2 clinical trials, BASECAMP\nin pediatric participants with DMD and TRAILHEAD in adults living with DMD, as\nwell as for FSHD. The Company has identified additional muscle diseases and\ninjury conditions where restoring muscle repair and regeneration may have\ntherapeutic benefit and plans to pursue these opportunities in future clinical\ndevelopment. For more information, visit www.satellos.com and connect with\nSatellos on X\n(https://www.globenewswire.com/Tracker?data=HoQCxEPrNBUqhVJDCAS9s8ety-rDUrJxAR_gTpL5aHWZRiGsoXAL4Bj4DRYff2NB1RNTqyzu0vNVu8dq-I-lWA==),\nLinkedIn\n(https://www.globenewswire.com/Tracker?data=ZaMhtgFI-KCkI5PjQKyDPWCQSwdhrwTfqSJag29rjU86l83mXux1lYIjre9dTqov43R3MneTEu8iZgc5dQ2iP-kPvW09x75eu4gveIDlXT_6UvmtCXPXSk8V1JOxF7bO),\nFacebook\n(https://www.globenewswire.com/Tracker?data=0T06KhkQpxYXS6NbmXHd4V-q3OF7qrNhz4xrTfjwNLZFbppdiw4rdmV6sEbLHFbW80Op2NR7ILbgo08gwY9vzMcYzTG_riu39zzfEpGrVrs=)\nand Instagram\n(https://www.globenewswire.com/Tracker?data=-P72_I8TX39OQHyXaRoLqfCV47oiAFHU6NGzcPjrVR8kuCvan2-MeWp3ZoTEjW39p1fhJFgR4jsCmHXNdckyi1sNrjxBaJXSlt7Wdsig3zOie4Aa4S1KFZa-zb79YIG9).\n\nNOTICE ON FORWARD-LOOKING STATEMENTS\n\nThis press release includes forward-looking information or forward-looking\nstatements within the meaning of applicable securities laws regarding Satellos\nand its business, which may include, but are not limited to, statements\nregarding the possibility of pursuing regulatory approval for forazapadin, the\npotential for forazapadin to represent a disease modifying approach to the\ntherapeutic treatment of people living with DMD; anticipated benefits to\npatients from a small molecule treatment for DMD; the enrollment in,\nadvancement and timing of results of forazapadin through clinical trials,\nincluding the BASECAMP and TRAILHEAD clinical trials; the pharmacodynamic\nproperties and mechanism-of-action of forazapadin; the potential of our\napproach in other degenerative muscle diseases and Satellos’ plans to pursue\nadditional muscle diseases and injury conditions in future clinical\ndevelopment; forazapadin's prospective impact on DMD patients, patients with\nother degenerative muscle disease or muscle injury or trauma, and on muscle\nregeneration generally, including whether results observed in the TRAILHEAD\nstudy will continue to mature or will translate to the pediatric population\nstudied in BASECAMP; the anticipated timing for an Investigational New Drug\nsubmission to the U.S. Food and Drug Administration for forazapadin for\nevaluation in facioscapulohumeral muscular dystrophy and the anticipated\ntiming for the launch of a related Phase 2 clinical trial; Satellos'\ntechnologies and drug development plans; and the company’s expectations\nregarding the sufficiency of its cash, cash equivalents and short-term\ninvestments to fund operations, including its expectation that its current\ncash resources will provide a runway through 2027. All statements that are, or\ninformation which is, not historical facts, including without limitation,\nstatements regarding future estimates, plans, programs, forecasts,\nprojections, objectives, assumptions, expectations or beliefs of future\nperformance, occurrences or developments, are “forward-looking information\nor statements.” Often, but not always, forward-looking information or\nstatements can be identified by the use of words such as “shall”,\n“intends”, “believe”, “plan”, “expect”, “intend”,\n“estimate”, “anticipate”, “potential”, “prospective”,\n“assert” or any variations (including negative or plural variations) of\nsuch words and phrases, or state that certain actions, events or results\n“may”, “might”, “can”, “could”, “would” or “will” be\ntaken, occur, lead to, result in, or, be achieved. Such statements are based\non the current expectations and views of future events of the management of\nthe Company. These statements are based on assumptions and subject to risks\nand uncertainties. In making forward looking statements, the Company has\nrelied on various assumptions, including but not limited to: its ability to\nobtain future funding on favorable terms, if at all; obtaining positive\nresults in its clinical trials, its ability to obtain necessary regulatory\napprovals; its ability to arrange for the manufacturing of its product\ncandidates and technologies; and general business, market and economic\nconditions. Although management believes that the assumptions underlying these\nstatements are reasonable, they may prove to be incorrect. The forward-looking\nevents and circumstances discussed in this release, may not occur and could\ndiffer materially as a result of known and unknown risk factors and\nuncertainties affecting the Company, including, without limitation, risks\nrelating to the pharmaceutical and bioscience industry (including the risks\nassociated with preclinical and clinical trials and regulatory approvals), the\nresearch and development of therapeutics, the results of preclinical and\nclinical trials, general market conditions and equity markets, economic\nfactors and management's ability to manage and to operate the business of the\nCompany generally, including inflation and the costs of operating a biopharma\nbusiness, and those risks and uncertainties described in more detail in the\n“Risk Factors” section of Satellos' Annual Information Form dated March\n27, 2026, and amended and restated short form base shelf prospectus dated\nAugust 11, 2026 (each of which is located on Satellos' SEDAR+ profile) and\nincorporated by reference in Satellos’ Form F-10 filed with the Securities\nand Exchange Commission on August 11, 2026, and in Satellos' public filings on\nEDGAR (sec.gov) and SEDAR+ (sedarplus.ca). Although Satellos has attempted to\nidentify important factors that could cause actual actions, events or results\nto differ materially from those described in forward-looking statements, there\nmay be other factors that cause actions, events or results to differ from\nthose anticipated, estimated or intended. Accordingly, readers should not\nplace undue reliance on any forward-looking statements or information. No\nforward-looking statement can be guaranteed. Except as required by applicable\nsecurities laws, forward-looking statements speak only as of the date on which\nthey are made and Satellos does not undertake any obligation to publicly\nupdate or revise any forward-looking statement, whether resulting from new\ninformation, future events, or otherwise.\n\nCONTACTS\n\nInvestors: Caitlin Lowie, Vice President, Investor Relations & Communications,\nir@satellos.com\n\nMedia: Emily Williams, Senior Director, Communications, media@satellos.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/3fe5e759-e0bb-4bc7-9979-e58a67f5f684)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX4rvdg1-20260909","title":"Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247","author":"Globe Newswire","ticker":"MSLE","created":"2026-09-09T11:00:01.356Z","tickers":["MSLE","MSCL"],"exchange":"NASDAQ","article_body":"TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience (Nasdaq: MSLE,\nTSX: MSCL), a clinical-stage drug development company developing\nlife-improving medicines to treat degenerative muscle diseases, today\nannounced the assignment of the International Nonproprietary Name (INN)\n“forazapadin” for the Company's orally administered, small molecule drug\ncandidate designed to restore muscle regeneration that was previously known as\nSAT-3247.\n\n“As we continue to execute our clinical development strategies, this naming\ndesignation reflects the maturity of the program and supports its future\ndevelopment as we plan for regulatory submission and commercialization in\nDuchenne muscular dystrophy,” said Frank Gleeson, co-founder and chief\nexecutive officer of Satellos. “Importantly, it comes amid a period of\nsignificant momentum across our Duchenne clinical programs, notably the\nexpected completion of enrollment this quarter in the BASECAMP study and the\nrelease of clinical data from the BASECAMP study, which is expected in the\nfourth quarter.”\n\nThe INN, assigned through the World Health Organization naming process,\nestablishes a globally recognized, nonproprietary name for the therapy as\nforazapadin advances through clinical development and toward potential\ncommercialization. Forazapadin is currently being evaluated in two Phase 2\nstudies in patients with Duchenne muscular dystrophy (DMD) and the company\nintends to begin a Phase 2 clinical trial in facioscapulohumeral muscular\ndystrophy (FSHD) by the end of 2026.\n\nABOUT FORAZAPADIN\n\nForazapadin is a proprietary, oral, small molecule drug candidate being\ndeveloped by Satellos as a novel approach to regenerating skeletal muscle lost\nin DMD and other degenerative muscle diseases or injury conditions.\nForazapadin targets AAK1, a key protein identified by Satellos as capable of\nhelping restore the body’s natural muscle repair and regeneration biology, a\nfundamental process that is disrupted in DMD and other degenerative\nconditions. By inhibiting AAK1, forazapadin treatment aims to re-establish a\nbiochemical signal needed to support muscle regeneration. Satellos is\nadvancing forazapadin as a potential treatment for DMD that is independent of\ndystrophin and applicable regardless of exon mutation status as either a\nstand-alone or adjunctive therapy, with ongoing Phase 2 clinical studies\nincluding BASECAMP, a global, randomized, placebo-controlled study in\npediatric participants, and TRAILHEAD, an open-label study in adult\nparticipants.\n\nThe Company previously referred to the program as SAT-3247 and expects to\ntransition to broader use of the INN in future scientific, regulatory and\ncorporate communications.\n\nABOUT SATELLOS BIOSCIENCE INC.\n\nSatellos is a clinical-stage drug development company focused on restoring\nnatural muscle repair and regeneration in degenerative muscle diseases.\nThrough its research, Satellos has developed forazapadin, an orally\nadministered small molecule AAK1 inhibitor designed to address deficits in\nmuscle repair and regeneration. Forazapadin is being evaluated as a potential\ndisease-modifying treatment, for DMD in two Phase 2 clinical trials, BASECAMP\nin pediatric participants with DMD and TRAILHEAD in adults living with DMD, as\nwell as for FSHD. The Company has identified additional muscle diseases and\ninjury conditions where restoring muscle repair and regeneration may have\ntherapeutic benefit and plans to pursue these opportunities in future clinical\ndevelopment. For more information, visit www.satellos.com and connect with\nSatellos on X\n(https://www.globenewswire.com/Tracker?data=HoQCxEPrNBUqhVJDCAS9s8ety-rDUrJxAR_gTpL5aHWZRiGsoXAL4Bj4DRYff2NB1RNTqyzu0vNVu8dq-I-lWA==),\nLinkedIn\n(https://www.globenewswire.com/Tracker?data=ZaMhtgFI-KCkI5PjQKyDPWCQSwdhrwTfqSJag29rjU86l83mXux1lYIjre9dTqov43R3MneTEu8iZgc5dQ2iP-kPvW09x75eu4gveIDlXT_6UvmtCXPXSk8V1JOxF7bO),\nFacebook\n(https://www.globenewswire.com/Tracker?data=0T06KhkQpxYXS6NbmXHd4V-q3OF7qrNhz4xrTfjwNLZFbppdiw4rdmV6sEbLHFbW80Op2NR7ILbgo08gwY9vzMcYzTG_riu39zzfEpGrVrs=)\nand Instagram\n(https://www.globenewswire.com/Tracker?data=-P72_I8TX39OQHyXaRoLqfCV47oiAFHU6NGzcPjrVR8kuCvan2-MeWp3ZoTEjW39p1fhJFgR4jsCmHXNdckyi1sNrjxBaJXSlt7Wdsig3zOie4Aa4S1KFZa-zb79YIG9).\n\nNOTICE ON FORWARD-LOOKING STATEMENTS\n\nThis press release includes forward-looking information or forward-looking\nstatements within the meaning of applicable securities laws regarding Satellos\nand its business, which may include, but are not limited to, statements\nregarding the possibility of pursuing regulatory approval for forazapadin, the\npotential for forazapadin to represent a disease modifying approach to the\ntherapeutic treatment of people living with DMD; anticipated benefits to\npatients from a small molecule treatment for DMD; the enrollment in,\nadvancement and timing of results of forazapadin through clinical trials,\nincluding the BASECAMP and TRAILHEAD clinical trials; the pharmacodynamic\nproperties and mechanism-of-action of forazapadin; the potential of our\napproach in other degenerative muscle diseases and Satellos’ plans to pursue\nadditional muscle diseases and injury conditions in future clinical\ndevelopment; forazapadin's prospective impact on DMD patients, patients with\nother degenerative muscle disease or muscle injury or trauma, and on muscle\nregeneration generally, including whether results observed in the TRAILHEAD\nstudy will continue to mature or will translate to the pediatric population\nstudied in BASECAMP; the anticipated timing for an Investigational New Drug\nsubmission to the U.S. Food and Drug Administration for forazapadin for\nevaluation in facioscapulohumeral muscular dystrophy and the anticipated\ntiming for the launch of a related Phase 2 clinical trial; Satellos'\ntechnologies and drug development plans; and the company’s expectations\nregarding the sufficiency of its cash, cash equivalents and short-term\ninvestments to fund operations, including its expectation that its current\ncash resources will provide a runway through 2027. All statements that are, or\ninformation which is, not historical facts, including without limitation,\nstatements regarding future estimates, plans, programs, forecasts,\nprojections, objectives, assumptions, expectations or beliefs of future\nperformance, occurrences or developments, are “forward-looking information\nor statements.” Often, but not always, forward-looking information or\nstatements can be identified by the use of words such as “shall”,\n“intends”, “believe”, “plan”, “expect”, “intend”,\n“estimate”, “anticipate”, “potential”, “prospective”,\n“assert” or any variations (including negative or plural variations) of\nsuch words and phrases, or state that certain actions, events or results\n“may”, “might”, “can”, “could”, “would” or “will” be\ntaken, occur, lead to, result in, or, be achieved. Such statements are based\non the current expectations and views of future events of the management of\nthe Company. These statements are based on assumptions and subject to risks\nand uncertainties. In making forward looking statements, the Company has\nrelied on various assumptions, including but not limited to: its ability to\nobtain future funding on favorable terms, if at all; obtaining positive\nresults in its clinical trials, its ability to obtain necessary regulatory\napprovals; its ability to arrange for the manufacturing of its product\ncandidates and technologies; and general business, market and economic\nconditions. Although management believes that the assumptions underlying these\nstatements are reasonable, they may prove to be incorrect. The forward-looking\nevents and circumstances discussed in this release, may not occur and could\ndiffer materially as a result of known and unknown risk factors and\nuncertainties affecting the Company, including, without limitation, risks\nrelating to the pharmaceutical and bioscience industry (including the risks\nassociated with preclinical and clinical trials and regulatory approvals), the\nresearch and development of therapeutics, the results of preclinical and\nclinical trials, general market conditions and equity markets, economic\nfactors and management's ability to manage and to operate the business of the\nCompany generally, including inflation and the costs of operating a biopharma\nbusiness, and those risks and uncertainties described in more detail in the\n“Risk Factors” section of Satellos' Annual Information Form dated March\n27, 2026, and amended and restated short form base shelf prospectus dated\nAugust 11, 2026 (each of which is located on Satellos' SEDAR+ profile) and\nincorporated by reference in Satellos’ Form F-10 filed with the Securities\nand Exchange Commission on August 11, 2026, and in Satellos' public filings on\nEDGAR (sec.gov) and SEDAR+ (sedarplus.ca). Although Satellos has attempted to\nidentify important factors that could cause actual actions, events or results\nto differ materially from those described in forward-looking statements, there\nmay be other factors that cause actions, events or results to differ from\nthose anticipated, estimated or intended. Accordingly, readers should not\nplace undue reliance on any forward-looking statements or information. No\nforward-looking statement can be guaranteed. Except as required by applicable\nsecurities laws, forward-looking statements speak only as of the date on which\nthey are made and Satellos does not undertake any obligation to publicly\nupdate or revise any forward-looking statement, whether resulting from new\ninformation, future events, or otherwise.\n\nCONTACTS\n\nInvestors: Caitlin Lowie, Vice President, Investor Relations & Communications,\nir@satellos.com\n\nMedia: Emily Williams, Senior Director, Communications, media@satellos.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/3fe5e759-e0bb-4bc7-9979-e58a67f5f684)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-09T11:00:01.456196151Z","server_sent_at_ms":1788951601456},"received_at":"2026-09-09T11:00:01.508Z","source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358479/0/en/satellos-announces-forazapadin-as-assigned-international-nonproprietary-name-for-lead-drug-candidate-sat-3247.html"},"analysis":{"id":"127692","press_release_id":"138849","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Clinical-stage, pre-revenue biotech; stated cash runway only 'through 2027' implies future financing likely"],"eventType":"operations_update","narrative":"Satellos Bioscience announced the World Health Organization has assigned the International Nonproprietary Name 'forazapadin' to its lead drug candidate previously known as SAT-3247, an oral small molecule AAK1 inhibitor designed to restore muscle regeneration.\n\nForazapadin is in two Phase 2 Duchenne muscular dystrophy trials -- BASECAMP in pediatric participants and TRAILHEAD in adults -- with BASECAMP enrollment expected to complete this quarter and clinical data expected in the fourth quarter.\n\nThe company framed the INN as a maturity milestone supporting planned regulatory submission and commercialization, and intends to begin a Phase 2 FSHD trial by the end of 2026.\n\nIn forward-looking statements, management reiterated its expectation that current cash resources will fund operations through 2027.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"INN assignment for lead asset forazapadin positions Satellos ahead of the Q4 BASECAMP DMD data readout -- a naming housekeeping event, but it flags the near-term catalyst."},"keyFigures":{"drugName":"forazapadin (formerly SAT-3247)","phaseOfTrial":"Phase 2","customDimensions":{"mechanism":"oral small molecule AAK1 inhibitor, dystrophin-independent","cash_runway":"through 2027","basecamp_data_release":"expected Q4 2026","fshd_ind_and_phase2_start":"by end of 2026","basecamp_enrollment_completion":"expected this quarter (Q3 2026)"}},"quotedText":"this naming designation reflects the maturity of the program and supports its future development as we plan for regulatory submission and commercialization in Duchenne muscular dystrophy","namedEntities":{"people":[{"name":"Frank Gleeson","role":"co-founder and CEO of Satellos"},{"name":"Caitlin Lowie","role":"Vice President, Investor Relations & Communications"},{"name":"Emily Williams","role":"Senior Director, Communications"}],"products":["forazapadin","SAT-3247","BASECAMP study","TRAILHEAD study"],"companies":[{"name":"Satellos Bioscience","ticker":"MSLE","relationship":"filer"},{"name":"World Health Organization","relationship":"INN naming authority"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"INN assignment is a procedural naming milestone signaling program maturity ahead of regulatory submission, not new clinical, regulatory, or financial data. The clinically meaningful catalysts (BASECAMP enrollment completion and Q4 data release) are only referenced as upcoming events."},"tickerRelevance":{"others":[{"ticker":"MSCL","relevance":"dual listing on TSX (same company)"}],"primary":"MSLE"},"globalImportance":18,"audienceRelevance":15,"eventTypeSecondary":["clinical_trial"],"importanceComponents":{"tickerTier":"micro-cap clinical-stage biotech","eventGravity":"procedural INN naming milestone, no new clinical or financial data","sectorWeight":"biotech audience watches naming as pre-commercial signal","issuerAuthored":true,"upcomingCatalystFlag":"BASECAMP Q4 2026 data release referenced"}},"event_type":"operations_update","event_type_secondary":["clinical_trial"],"sentiment":"bullish","material_impact_score":2,"narrative":"Satellos Bioscience announced the World Health Organization has assigned the International Nonproprietary Name 'forazapadin' to its lead drug candidate previously known as SAT-3247, an oral small molecule AAK1 inhibitor designed to restore muscle regeneration.\n\nForazapadin is in two Phase 2 Duchenne muscular dystrophy trials -- BASECAMP in pediatric participants and TRAILHEAD in adults -- with BASECAMP enrollment expected to complete this quarter and clinical data expected in the fourth quarter.\n\nThe company framed the INN as a maturity milestone supporting planned regulatory submission and commercialization, and intends to begin a Phase 2 FSHD trial by the end of 2026.\n\nIn forward-looking statements, management reiterated its expectation that current cash resources will fund operations through 2027.","key_figures":{"drugName":"forazapadin (formerly SAT-3247)","phaseOfTrial":"Phase 2","customDimensions":{"mechanism":"oral small molecule AAK1 inhibitor, dystrophin-independent","cash_runway":"through 2027","basecamp_data_release":"expected Q4 2026","fshd_ind_and_phase2_start":"by end of 2026","basecamp_enrollment_completion":"expected this quarter (Q3 2026)"}},"named_entities":{"people":[{"name":"Frank Gleeson","role":"co-founder and CEO of Satellos"},{"name":"Caitlin Lowie","role":"Vice President, Investor Relations & Communications"},{"name":"Emily Williams","role":"Senior Director, Communications"}],"products":["forazapadin","SAT-3247","BASECAMP study","TRAILHEAD study"],"companies":[{"name":"Satellos Bioscience","ticker":"MSLE","relationship":"filer"},{"name":"World Health Organization","relationship":"INN naming authority"}],"dollarAmounts":[]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-09T11:06:18.023Z","global_importance":18,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap clinical-stage biotech","eventGravity":"procedural INN naming milestone, no new clinical or financial data","sectorWeight":"biotech audience watches naming as pre-commercial signal","issuerAuthored":true,"upcomingCatalystFlag":"BASECAMP Q4 2026 data release referenced"}},"durationMs":43371,"modelName":"glm-5.3-flash"}}